HAINAN POLY PHARM. CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.67 CNY | +0.96% |
|
+1.10% | -35.15% |
| 08/04 | Hainan Poly Pharm Gets Nod to Market Voriconazole Injection in Sweden | MT |
| 04/04 | Hainan Poly Pharm Gets Nod to Market Skin Infection Drug in Germany | MT |
| Sales 2023 * | 2.05B 283M 23.6B | Sales 2024 * | 2.38B 328M 27.35B | Capitalization | 6.58B 908M 75.72B |
|---|---|---|---|---|---|
| Net income 2023 * | 473M 65.28M 5.44B | Net income 2024 * | 550M 75.9M 6.33B | EV / Sales 2023 * | 3.21 x |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 2.77 x |
| P/E ratio 2023 * |
13.8
x | P/E ratio 2024 * |
11.8
x | Employees | 1,522 |
| Yield 2023 * |
0.55% | Yield 2024 * |
0.68% | Free-Float | 57.56% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.96% | ||
| 1 week | +1.10% | ||
| Current month | -17.72% | ||
| 1 month | -18.82% | ||
| 3 months | -23.03% | ||
| 6 months | -27.73% | ||
| Current year | -35.15% |
1 week
14.06
14.83
1 month
13.3918.55
Current year
13.3923.55
1 year
13.3932.50
3 years
13.3956.66
5 years
13.3956.66
10 years
4.0056.66
| Managers | Title | Age | Since |
|---|---|---|---|
Min Hua Fan
CEO | Chief Executive Officer | 63 | 14/92/14 |
Tong Ning Luo
DFI | Director of Finance/CFO | 49 | 01/04/01 |
Ji Ping Wang
BRD | Director/Board Member | 52 | 01/10/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shu Ge Jiao
BRD | Director/Board Member | 58 | 01/15/01 |
Min Hua Fan
CEO | Chief Executive Officer | 63 | 14/92/14 |
Hui Fang Xie
BRD | Director/Board Member | 43 | 01/04/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 14.67 | +0.96% | 13,841,170 |
| 25/24/25 | 14.53 | 0.00% | 14,785,200 |
| 24/24/24 | 14.53 | +0.14% | 15,032,040 |
| 23/24/23 | 14.51 | +0.48% | 13,104,800 |
| 22/24/22 | 14.44 | -0.48% | 13,309,220 |
End-of-day quote Shenzhen S.E., April 26, 2024
More quotes
Hainan Poly Pharm Co Ltd is a company engaged in research and development, production and sales of drugs. The Company operates five segments. The Anti-Allergic segment is engaged in the production of desloratadine dispersible tablets, desloratadine dry suspension and desloratadine tablets. The Antibiotic segment provides levofloxacin hydrochloride capsules and azithromycin dry suspension for the treatment of bacterial infections. The Nonsteroidal Anti-inflammatory Drugs segment provides diclofenac sodium enteric-coated sustained-release capsule products for the treatment of arthritis and dysmenorrhea. The Digestive segment is involved in providing trimebutine maleate tablets to treat abdominal pain, diarrhea, and irritable bowel syndrome. The Company also operates Other segment.
Sector
Pharmaceuticals
Calendar
30/04/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
14.67
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -35.15% | 908M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 300630 Stock
